The use of lipid-lowering drugs across ethnic groups in the secondary prevention of ischaemic heart disease: analysis of cross-sectional surveys in England

By Gill Paramjit S   Quirke Terry P   Mant Jonathan W   Allan Teresa F  

British Journal of General Practice, Vol. 54, Iss. 503, 2004-06 ,pp. : 442-443

Royal College of General Practitioners

Access to resources Recommend Favorite

Why do sales of lipid-lowering drugs vary between counties in Norway?

By Hartz Ingeborg   Njølstad Inger   Furu Kari   Skurtveit Svetlana   Elise Eggen Anne  

Scandinavian Journal of Primary Health Care, Vol. 24, Iss. 2, 2006-06 ,pp. : 115-121

Informa Healthcare

Access to resources Recommend Favorite

How do patients at risk portray candidates for coronary heart disease? A qualitative interview study

By Frich Jan C.   Malterud Kirsti   Fugelli Per  

Scandinavian Journal of Primary Health Care, Vol. 25, Iss. 2, 2007-01 ,pp. : 112-116

Informa Healthcare

Access to resources Recommend Favorite

Soy protein, soybean isoflavones and coronary heart disease risk: where do we stand?

By Messina Mark   Lane Branin  

Future Lipidology, Vol. 2, Iss. 1, 2007-02 ,pp. : 55-74

Future Medicine

Access to resources Recommend Favorite

Lipoprotein predictors of cardiovascular events in statin-treated patients with coronary heart disease. Insights from the Incremental Decrease in End-points through Aggressive Lipid-lowering Trial (IDEAL)

By Holme Ingar   Cater Nilo   Faergeman Ole   Kastelein John   Olsson Anders   Tikkanen Matti   Lytken Larsen Mogens   Lindahl Christina   Pedersen Terje  

Annals of Medicine, Vol. 40, Iss. 6, 2008-01 ,pp. : 456-464

Informa Healthcare

Access to resources Recommend Favorite